title: Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis.
abstract: OBJECTIVE
  To present the findings of a risk-stratification survival analysis with use of data collected on a heterogeneous group of patients with hepatocellular carcinoma (HCC) treated with TheraSphere.
  
  
  METHODS
  Baseline, treatment, and follow-up data were collected and analyzed from 121 TheraSphere-treated patients. Survival analyses were performed to identify those variables most strongly associated with 3-month mortality. The presence of any of the identified risk variables resulted in the assignment of a patient to the high-risk category.
  
  
  RESULTS
  Five liver reserve and two non-liver reserve variables were identified and used to stratify patients into low- or high-risk groups. Sixteen of the 33 patients assigned to the high-risk group (49%) did not survive the first 3 months after treatment, compared with six of the 88 patients assigned to the low-risk group (7%; Fisher exact test, P < .0001). Median survival for the low- and high-risk groups were 466 days and 108 days, respectively (hazard ratio, 6.0; P < .0001). Eleven of 12 patients who experienced a treatment-related major complication ending in death were included in the high-risk group. No single variable explained the major complication relationship to treatment.
  
  
  CONCLUSIONS
  Patients with HCC who are being considered for treatment with TheraSpheres should be evaluated for the presence of the risk variables described herein. The absence of these variables is predictive of improved survival (median of 466 days) compared with patients at high risk (median of 108 days).
authors.affiliation: DataMedix Corporation, Brookhaven, Pennsylvania, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Goin
authors.forename: Riad
authors.initials: R
authors.lastname: Salem
authors.forename: Brian I
authors.initials: BI
authors.lastname: Carr
authors.forename: Janet E
authors.initials: JE
authors.lastname: Dancey
authors.forename: Michael C
authors.initials: MC
authors.lastname: Soulen
authors.forename: Jean-Francois H
authors.initials: JF
authors.lastname: Geschwind
authors.forename: Kathleen
authors.initials: K
authors.lastname: Goin
authors.forename: Mark
authors.initials: M
authors.lastname: Van Buskirk
authors.forename: Kenneth
authors.initials: K
authors.lastname: Thurston
mesh_terms: D000368:Aged; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D002423:Cause of Death; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006499:Hepatic Artery; D006801:Humans; D008099:Liver / Q000503:physiopathology / Q000528:radiation effects; D008113:Liver Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D008297:Male; D008863:Microspheres; D020360:Neoadjuvant Therapy; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D018570:Risk Assessment; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes